Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Nickel nanoparticles activate cellular pathway that contributes to cancer in lung cells

All the excitement about nanotechnology comes down to this: Structures of materials at the scale of billionths of a meter take on unusual properties. Technologists often focus on the happier among these newfound capabilities, but new research by an interdisciplinary team of scientists at Brown University finds that nanoparticles of nickel activate a cellular pathway that contributes to cancer in human lung cells.

24 Aug 2011

Elderly women with sleep apnea more likely to develop dementia

Elderly women who suffer from sleep apnea -- characterized by disrupted breathing and sleep and a reduction in the intake of oxygen -- are about twice as likely to develop dementia in the next five years as those without the condition, according to a multi-center study led by researchers from the University of California, San Francisco.

10 Aug 2011

Researchers discover lack of oxygen in the lungs after mold invasion

Researchers led by Montana State University have found a surprising condition that occurs in the lungs after an invasion of a common mold that can cause deadly infections in humans.

6 Aug 2011

Boston Therapeutics files chewable metformin ANDA with FDA to treat diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, today announced that it has submitted an Abbreviated New Drug Application (ANDA) for chewable metformin with the U.S. Food and Drug Administration.

4 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Class I recall for Vital Signs HCH/Anesthesia Breathing Circuit

In April 2011, Vital Signs Devices, a GE Healthcare Company, initiated a voluntary worldwide field correction of the Vital Signs Hygroscopic Condenser Humidifier (HCH)/Anesthesia Breathing Circuit.

30 Jul 2011

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH.

29 Jul 2011

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company's lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.

27 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Tocotrienol could help reduce stroke damage

Preventive supplementation with a natural form of vitamin E called tocotrienol could help reduce brain damage caused by strokes, researchers reported today at the 2nd International Conference on Tocotrienols and Chronic Diseases.

15 Jul 2011

Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

13 Jul 2011

Software program could protect Florida's lakes, rivers from pollutants

As a young scholar, Fernando Rios loved science and computer programming equally. So when Rios - who holds a bachelor's degree in physics from Canada's University of Waterloo - went looking for a graduate program, he discovered the Department of Scientific Computing at Florida State University, which has about 35 graduate students and launched a new undergraduate program of computational sciences in fall 2010.

7 Jul 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

Actelion awards grants to 2011 ENTELLIGENCE young investigators for research in pulmonary arterial hypertension

Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the ENTELLIGENCE program supported by Actelion. The announcement was made at an awards luncheon, during which the recipients of the 2011 awards gave an overview of their proposed work.

14 Jun 2011

Untreated obstructive sleep apnea can reduce work productivity

Large corporations could save millions of dollars in lost productivity by screening and treating high-risk employees for obstructive sleep apnea, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.

14 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011